The Leukemia & Lymphoma Society’s New Chief Scientific Officer Excited about What’s Next in Blood Cancer Research | Leukemia and Lymphoma Society
By The Leukemia & Lymphoma Society | January 17, 2025 “It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,” says Dr. Gruenbaum. As CSO, Gruenbaum is responsible for setting the strategy for the multi-million-dollar funding of LLS’ comprehensive grant programs, the unique Beat AML® Master Clinical Trial, and a growing number of biotech partnerships via the Therapy Acceleration Program. This comprehensive strategy is designed
